SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Hinge Health, Inc. (HNGE) has a negative trailing P/E of -5.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 20.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -17.85%, forward earnings yield 5.00%. PEG 1.10.
Criteria proven by this page:
- VALUE (90/100, Pass) — analyst target implies upside (+46.7%).
- Forward P/E 20.0 — analysts expect a return to profitability with estimated EPS of $1.94 for FY2026.
- PEG Ratio 1.10 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Trailing Earnings Yield -17.85% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 5.00% as earnings recover.
- Analyst consensus target $56.88 (+46.7% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 58/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
90/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
75/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HNGE
Valuation Multiples
P/E (TTM)-5.6
Forward P/E20.0
PEG Ratio1.10
Forward PEG1.10
P/B Ratio7.82
P/S Ratio4.99
EV/EBITDA-5.2
Per Share Data
EPS (TTM)$-6.64
Forward EPS (Est.)$1.94
Book Value / Share$4.76
Revenue / Share$7.39
FCF / Share$2.10
Yields & Fair Value
Earnings Yield-17.85%
Forward Earnings Yield5.00%
Dividend Yield0.00%
SharesGrow IV$85.45 (+120.3%)
Analyst Target$56.88 (+46.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2023 |
-27.1 |
0.00 |
6.86 |
10.01 |
- |
| 2024 |
-245.6 |
2.75 |
7.03 |
7.51 |
- |
| 2025 |
-7.0 |
0.00 |
9.72 |
6.26 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2023 |
$0.00 |
$292.73M |
$-108.14M |
-36.9% |
| 2024 |
$0.00 |
$390.4M |
$-11.93M |
-3.1% |
| 2025 |
$-5.19 |
$587.86M |
$-528.26M |
-89.9% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$1.94 |
$1.68 – $2.13 |
$736.57M |
$732M – $742.86M |
8 |
| 2027 |
$2.29 |
$1.99 – $2.55 |
$871.34M |
$850.69M – $903.43M |
9 |
| 2028 |
$3.01 |
$2.81 – $3.21 |
$1.02B |
$1.02B – $1.02B |
2 |
| 2029 |
$3.38 |
$3.29 – $3.50 |
$1.24B |
$1.21B – $1.27B |
1 |
| 2030 |
$3.79 |
$3.68 – $3.93 |
$1.41B |
$1.38B – $1.45B |
1 |
